Comments on Draft Scoping Document for CGRP Inhibitors for Migraine Prevention

The Institute for Patient Access raised several concerns during ICER’s open input period. Based on the methodology described in the draft scoping document, however, it does not appear that ICER’s cost-effectiveness evaluation will adequately address these issues.

Read the Comments


Categorized in: